Pharmaceuticals News and Research

RSS

FDA grants priority review status to Avedro's riboflavin ophthalmic solution/KXL system

Avedro Inc, a Boston-based ophthalmic medical device and pharmaceutical company announces that it received notification from the U.S. Food and Drug Administration stating that their NDA for riboflavin ophthalmic solution/KXL system has been filed, and has been granted priority review status. The priority review status places the application action date at March 15th, 2014.

25 Nov 2013

Researchers show for first time how influenza A viruses infect respiratory cells

Researchers at the University of California, San Diego School of Medicine have shown for the first time how influenza A viruses snip through a protective mucus net to both infect respiratory cells and later cut their way out to infect other cells.

25 Nov 2013

Researchers identify potential therapeutic target in treatment of certain AML

Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.

25 Nov 2013

DSMB reviews safety data from Phase I/IIa clinical trial of NTCELL for Parkinson’s disease

Living Cell Technologies Limited today announced that the independent data safety monitoring board has reviewed the safety data from the initial patient in the Phase I/IIa clinical trial of NTCELL and advised that implants for the additional three patients in the trial can proceed.

25 Nov 2013

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco.

25 Nov 2013

Japanese health authorities approve Aerocrine's NIOX MINO for assessing airway inflammation

Aerocrine AB announces today that Japanese health authorities have approved the use of its FeNO-measuring device NIOX MINO as a tool for assessing patients with airway inflammation such as asthma.

25 Nov 2013

CHMP recommends approval of Otsuka's Deltyba for pulmonary multidrug-resistant tuberculosis

Otsuka Pharmaceutical Co., Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Deltyba (delamanid) in combination with a WHO recommended optimized background regimen for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB). The CHMP opinion will help form the basis for a European Commission decision expected early next year.

25 Nov 2013

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

Janssen-Cilag International NV announced today that the European Commission has approved INVOKANA (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control[1]. Canagliflozin is an oral, once-daily medication, which belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors.

23 Nov 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has received approval for the treatment of Macular Edema Following Central Retinal Vein Occlusion from the Japanese Ministry of Health, Labour and Welfare.

22 Nov 2013

Pharmaceutical powder characterisation and inhaler testing workshop to include expert presentations

A new workshop organised by Monash University will include invited presentations from Copley Scientific, the world’s leading provider of inhaler testing equipment, Freeman Technology, global leaders in the field of powder characterisation, and ATA Scientific, distributors of Malvern Panalytical materials characterisation systems.

From Malvern Panalytical 21 Nov 2013

Probe to measure immune function could lead to determine nanoparticle-based drugs for cancer patients

The development of a probe to measure the body's immune function could lead to more accurate, individualized doses for cancer patients prescribed nanoparticle-based drugs, according to research conducted at the University of North Carolina.

21 Nov 2013

Multiple sclerosis researchers receive NMSS drug development grant

A $500,000 drug development grant from the National Multiple Sclerosis Society was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company. Dr. Patrizia Casaccia, MD, PhD, Professor in the Departments of Neuroscience and Genetics and Genomics, at Icahn School of Medicine at Mount Sinai, will be the academic lead.

21 Nov 2013

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

What we are trying to do is take a cancer model like the PDX model (patient-derived tumor xenograft), which is a human-derived cancer growing in an in vivo model and apply radiation to that model.

From Xstrahl 20 Nov 2013

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Inovio Pharmaceuticals, Inc. announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon DNA vaccine to prevent and treat this deadly virus.

20 Nov 2013

Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases

Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific collaboration agreement with Advanced Accelerator Applications, a fast growing international player in Molecular Nuclear Medicine. The financial terms of the deal have not been disclosed.

20 Nov 2013

NeutroPhase irrigation therapy and NPWT help treat severe flesh eating and wound infections

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced the publication of a scientific paper by Dr. John R. Crew of Seton Medical Center, Daly City, California, describing the first use of adjunctive NeutroPhase irrigation therapy in conjunction with Negative Pressure Wound Therapy to successfully manage the severely-infected wound in the arm of a patient with life-threatening 'flesh-eating' disease.

20 Nov 2013

Stroke may be associated with smoking synthetic marijuana

Add stroke to the list of severe health hazards that may be associated with smoking synthetic marijuana, popularly known as spice or K2, a University of South Florida neurology team reports.

20 Nov 2013

Overall contribution from New Jersey hospitals to Garden State economy surpasses $20 billion

New Jersey hospitals contributed $20.4 billion to the Garden State economy in 2012, according to the 2013 N.J. Hospitals Economic Impact Report released today by the New Jersey Hospital Association. This is the first time in the six years NJHA has published this report that the overall contribution from hospitals surpassed $20 billion.

20 Nov 2013

Scientists at Salk Institute develop novel platform to study kidney diseases

Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.

19 Nov 2013

Pharmaceuticals News and Research

FDA grants priority review status to Avedro's riboflavin ophthalmic solution/KXL system

Researchers show for first time how influenza A viruses infect respiratory cells

Researchers identify potential therapeutic target in treatment of certain AML

DSMB reviews safety data from Phase I/IIa clinical trial of NTCELL for Parkinson’s disease

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

Japanese health authorities approve Aerocrine's NIOX MINO for assessing airway inflammation

CHMP recommends approval of Otsuka's Deltyba for pulmonary multidrug-resistant tuberculosis

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Pharmaceutical powder characterisation and inhaler testing workshop to include expert presentations

Probe to measure immune function could lead to determine nanoparticle-based drugs for cancer patients

Multiple sclerosis researchers receive NMSS drug development grant

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases

NeutroPhase irrigation therapy and NPWT help treat severe flesh eating and wound infections

Stroke may be associated with smoking synthetic marijuana

Overall contribution from New Jersey hospitals to Garden State economy surpasses $20 billion

Scientists at Salk Institute develop novel platform to study kidney diseases

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence